/

FULC

Fulcrum Therapeutics, Inc.Closed

3.68−0.07 −1.87%USD

NasdaqGM · as of Oct 13, 16:00 ET · 15m delayAfter hours 3.68 0.00%

Open

3.75

Prev close

3.75

Day range

3.683.75

52-week range

2.8315.74

Volume

1.46M0.94×

Mkt cap

281.09M

P/E ttm

—

Fwd P/E

-6.72

EPS ttm

-1.21

Div yield

0.00%

Earnings

—

From 52w high

−76.62%

Price Chart

Yahoo Finance · delayed

FULCOct 12, 2026O 3.77H 3.77L 3.73C 3.75−0.02 (−0.53%)Vol 1.61M

SMA 503.79
SMA 2006.36

1Y change −58.29% since Oct 10, 2025 close538 bars loadedTimes in America/New_YorkDraw from the left toolbar · click a drawing to edit · right-click for alerts and export

FULC Fulcrum Therapeutics, Inc. · Last Guard Finance

DES

Key Statistics

Yahoo Finance

Performance

1 week: +1.08%
1 month: −1.32%
3 months: +5.93%
6 months: −51.49%
Year to date: −66.84%
1 year: −58.29%

Valuation & ownership

Market cap: 281.09M
Enterprise value: −32.79M
P/E (ttm): —
Forward P/E: -6.72
PEG ratio: —
Price / book: 0.90
Price / sales (ttm): —
EV / EBITDA: 0.38
EPS (ttm): -1.21
EPS (forward): -0.5476
Beta (5y monthly): 2.63
Dividend yield: 0.00%
Payout ratio: 0.00%
Shares outstanding: 76.38M
Float: 63.49M
Short % of float: 9.41%
Short ratio (days): 4.90
Held by insiders: 3.35%
Held by institutions: 102.91%
Avg volume (3m): 1.55M
50-day average: 3.79
200-day average: 6.36
52-week change: −58.29%
S&P 500 52-week: +17.50%

Technicals (daily)

RSI (14): 49.2
vs 50-day SMA: −0.98%
vs 200-day SMA: −40.99%
50 / 200-day trend: ▼ 50 below 200
MACD vs signal: ▲ above
ATR (14) % of price: 1.93%
Realised vol (20d, ann.): 12.7%
From 52-week high: −76.18%
From 52-week low: +32.51%

ANR

Analyst Consensus

3 analysts

Consensus

—

Mean target

3.67

−0.36% implied

Low 3.00Median 4.00High 4.00

Recommendation trend

Now0 / 4 / 1
1m ago0 / 5 / 1

DES

About Fulcrum Therapeutics, Inc.

Yahoo Finance profile

Fulcrum Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops small molecules to improve the lives of patients with genetically defined diseases in the areas of high unmet medical need in the United States. Its clinical-stage product candidate is pociredir, a fetal hemoglobin inducer, which is in phase 1b clinical trial for the treatment of sickle cell disease and beta-thalassemia. The company also discovers programs for the treatment of diamond-blackfan anemia, Bone Marrow Failure Syndromes, novel fetal hemoglobin inducers, fibrotic disorders. It has licensce agreement with CAMP4 which includes certain small molecule compounds, composition of matter and method of use patent rights, and know-how to research, develop, manufacture, use, and commercialize. Fulcrum Therapeutics, Inc. was Incorporated in 2015 and is headquartered in Cambridge, Massachusetts.

Sector: Healthcare
Industry: Biotechnology
Employees: 9
Headquarters: Cambridge, MA, United States
Website: fulcrumtx.com
Officers: Mr. Alexander C. Sapir CEO, President & Director
Mr. Alan A. Musso C.M.A., CPA CFO, Treasurer & Principal Accounting Officer
Mr. Curtis G. Oltmans J.D. Chief Legal Officer, Head of External Affairs & Corporate Secretary

SEAS

Seasonality · FULC

2019–2026 · monthly returns

Strongest month Aug +41.26%Weakest month Apr −10.20%Averages use completed years only. Past seasonality doesn't predict future returns.

Year	Jan	Feb	Mar	Apr	May	Jun	Jul	Aug	Sep	Oct	Nov	Dec	Year
2026	-5.1	-21.9	-8.5	-7.0	-2.9	-47.1	-2.2	8.7	-4.9	-0.5			−67.5%
2025	-15.7	-9.3	-19.8	33.7	78.6	0.1	-2.2	-3.7	42.0	-4.9	25.0	3.4	+140.6%
2024	7.0	41.4	-7.5	-24.5	10.1	-21.0	49.7	-7.9	-58.2	-11.5	21.8	22.1	−30.4%
2023	73.2	-52.1	-52.8	-12.3	8.8	21.3	15.8	44.8	-19.7	-18.0	31.9	40.6	−7.3%
2022	-31.3	-9.5	115.0	-59.3	-26.0	-31.2	20.0	25.9	9.3	-31.3	23.2	6.3	−58.8%
2021	-5.6	14.0	-6.6	-4.5	-20.6	17.4	-30.2	306.3	-5.0	-21.5	-34.5	22.0	+51.1%
2020	3.6	9.7	-36.9	5.7	57.8	-8.1	-13.2	-54.2	9.1	24.3	15.9	2.4	−29.6%
2019								-22.3	-38.3	-5.6	97.0	34.7	+20.1%

INSD

Insider Activity · FULC

Market-wide insider buying →Congress trades →SEC Form 4 filings via Yahoo Finance

Buys, 6 months

417.6K shares

Sells, 6 months

18K shares

Net shares

+399.6K

Net change in insider shares

+18.50%

Date	Insider	Transaction	Shares	Value
Jul 16, 2026	Tang Kevin CBeneficial Owner of more than 10% of a Class of Security	Purchase at price 3.52 - 3.56 per share.	167.6K	$594.67K
Jul 14, 2026	Tang Kevin CBeneficial Owner of more than 10% of a Class of Security	Purchase at price 3.54 - 3.58 per share.	249.9K	$891.07K
Jun 25, 2026	Ezekowitz AlanDirector	Sale at price 3.65 per share.	18K	$65.61K
Feb 1, 2026	Gould Robert J.Director	Sale at price 10.72 per share.	15K	$160.86K
Jan 1, 2026	Gould Robert J.Director	Sale at price 11.87 per share.	15K	$178.09K
Jan 1, 2026	Gould Robert J.Director	Sale at price 10.87 per share.	15K	$163.09K
Dec 14, 2025	Oltmans Curtis GaleOfficer	Sale at price 12.92 per share.	3.5K	$44.60K
Dec 7, 2025	Ra Capital Healthcare Fund,L.P.Beneficial Owner of more than 10% of a Class of Security	Sale at price 13.33 - 14.98 per share.	4.18M	$58.38M
Nov 18, 2025	Gould Robert J.Director	Sale at price 11.03 per share.	15K	$165.50K
May 7, 2025	Tourangeau GregOfficer	Sale at price 5.06 per share.	498	$2.52K

13F

Investors Holding FULC

latest 13F filings of 29 followed managers

Investors holding FULC
Investor	Value	Of portfolio	Shares	Change	Quarter
Renaissance Technologies	$6.0M	0.01%	1.65M	+120×	Q2 2026

From each investor's quarterly 13F filing with the SEC: positions at the quarter's end, reported up to 45 days later. All investors

FULC

Price Chart

Keyboard shortcuts & functions

Anywhere

Command line

Charts (click the chart first)

Function codes

FULC

Price Chart

Key Statistics

Performance

Valuation & ownership

Technicals (daily)

Analyst Consensus

About Fulcrum Therapeutics, Inc.

Seasonality · FULC

Insider Activity · FULC

Congress Trades · FULC

Investors Holding FULC

Investors Holding FULC

Congress Trades · FULC

Seasonality · FULC

Insider Activity · FULC

Key Statistics

Performance

Valuation & ownership

Technicals (daily)

Analyst Consensus

About Fulcrum Therapeutics, Inc.

Financial Snapshot

Earnings & Dividends

News